

In the Specification

Please substitute the following paragraph on page 65, beginning at line 25 through page 66,
line 4:

Figure 1 Figures 1A-1B: (A) Multiple alignment generated by CLUSTALW of the full-length INSP052 (SEQ ID NO:16) polypeptide sequence, the mature, isolated extracellular domain INSP052 (INSP052EC, SEQ ID NO:22), and the closest related sequence identified in WO04/009834 (SEQIDNO434, SEQ ID NO:28) and SEQIDNO880, SEQ ID NO:32). (B) Multiple alignment generated by CLUSTALW comparing INSP052EC (SEQ ID NO:22) with the corresponding histidine tagged (INSP052EC-6His, SEQ ID NO:29) and Fc fusion (INSP052EC-FC, SEQ ID NO:30) versions of this sequence and with the Ig-domain-containing fragment of INSP052 (SEQ ID NO:16) (INSP052Ig2, SEQ ID NO:31). The Fc sequence corresponds to amino acids 246-477 of the constant region of human immunoglobulin lambda heavy chain IgG1; NCBI Acc. No. CAA75302. Underlined sequence denotes predicted signal peptide. Boxed sequence denotes predicted transmembrane domain. “*” indicates identical residues amongst the aligned sequences. “:” “:” indicates homologous residues amongst the aligned sequences.

Please substitute the following paragraphs on page 66, beginning at line 17 through page 67,
line 13:

Figure 5 Figures 5A-5B: inhibition of IL-5 (Interleukin 5; A) and IL-2 (Interleukin 2; B) secretion ConA-stimulated hPBMC mixed with increasing amount of INSP052EC-6His (expressed in log of the concentration of the protein in µg/ml). The IC50 value is indicated by the line interpolating the curve and the X/Y axis.

Figure 6 Figures 6A-6B: inhibition of IL-5 (Interleukin 5; A) and IL-2 (Interleukin 2; B) secretion by ConA-stimulated purified CD4+ T cells mixed with increasing amount of INSP052EC-6His (expressed in µg/ml). The effect can be compared to the values of cytokine secretion in presence or absence of ConA (YES, NO), and in presence of both ConA and Dexamethasone (Dex; 0.1 mg/kg).

Figure 7 Figures 7A-7B: INSP052EC-electrotransferred animals (pDEST12.2 INSP052-6HIS)

show a decrease of the blood levels of transaminases alanine aminotransferase (ALAT; A) and aspartate aminotransferase (ASAT; B) as compared to empty vector (pDEST12.2) control animals and human IL6-electrotransferred animals (pDEST12.2 hIL6-SII) 8 hours after the ConA challenge (see Example 6). The asterisks indicate the level of statistical significance of the decrease (the more asterisks, the more significant the decrease).

Figure 8 Figures 8A-8B: TNF-alpha and IL-6 cytokine levels in INSP052EC-6His- and hIL6-SII-electrotransferred animals (see Example 6 and Figure 7).

Figure 9 Figures 9A-9B: Effect of INSP052EC-6His administered in two dosages in mice then exposed to ConA. The blood levels of ASAT (A) and ALAT (B) were measured after 8 hours from ConA injection (see Example 6).

Figure 10 Figures 10A-10B: Effect of INSP052EC-6His injection prior to LPS administration on the release in the blood of IL-6 (A) or TNF alpha (B). The mice were treated with the protein at indicated concentration, with Dexamethasone (Dex; 0.1 mg/kg), or with the injection vehicle only (see Example 7). The asterisks indicate the level of statistical significance of the decrease (see Figure 7).

Please replace original pages 1-19 (Sequence Listing) submitted July 31, 2007 with new pages 1-20 attached hereto.